buprenorphine and naloxone tablet
1 INDICATIONS AND USAGE Buprenorphine and naloxone sublingual tablet is indicated for the maintenance treatment of opioid dependence. Buprenorphine and naloxone sublingual tablet should be used as part of a complete treatment plan that includes counseling and psychosocial support. Buprenorphine and naloxone sublingual tablet contains buprenorphine, a partial opioid agonist, and naloxone, an opioid antagonist, and is indicated for the maintenance treatment of opioid dependence. ( 1 ) Buprenorphine and naloxone sublingual tablet should be used as part of a complete treatment plan that includes counseling and psychosocial support. ( 1 )
sun pharmaceutical industries limited
ROUND ORANGE 970
Related Pills
buprenorphine and naloxone tablet
sun pharmaceutical industries limited
DISCLAIMER:
"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."
"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."
"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."
PillSync may earn a commission via links on our site
16 HOW SUPPLIED / STORAGE AND HANDLING
BUPRENORPHINE AND NALOXONE sublingual tablets containing 2 mg buprenorphine with 0.5 mg naloxone (in terms of free base, equivalent to 2.16 mg buprenorphine hydrochloride USP and 0.61 mg naloxone hydrochloride dihydrate USP) are uncoated, round, biconvex, orange, sublingual tablets, debossed with ‘969’ on one side and plain on other side and are supplied as: Bottles of 30 with child-resistant cap……....………..NDC 62756-969-83 Unit-Dose blister pack of 30 (3×10) tablets ……..... NDC 62756-969-64
BUPRENORPHINE AND NALOXONE sublingual tablets containing 8 mg buprenorphine with 2 mg naloxone (in terms of free base, equivalent to 8.64 mg buprenorphine hydrochloride USP and 2.44 mg naloxone hydrochloride dihydrate USP) are uncoated, round, biconvex, orange, sublingual tablets, debossed with ‘970’ on one side and plain on other side and are supplied as: Bottles of 30 with child-resistant cap…....…………..NDC 62756-970-83 Unit-Dose blister pack of 30 (3×10) tablets ……..... NDC 62756-970-64 Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° and 30°C (59° and 86°F) [see USP Controlled Room Temperature]. Store
BUPRENORPHINE AND NALOXONE sublingual tablets securely and dispose of properly [see Patient Counseling Information (17)].
More pills like ROUND 970